in the same syringe (called 'ketofol') has been shown to be a reliable and effective combination in shorter emergency procedures, paediatric cases and regional anaesthesia [9] [10] [11] . Ketamine and propofol have been observed to form no particles within the same injector at 23°C for one hour and they have been determined to be suitable for combined use 12 .
In the literature, we could find no study on the use of ketofol in ECT. We thought that by using subanaesthetic ketamine and low-dose propofol we could increase the seizure duration, provide haemodynamic stability and earlier recovery compared with the use of a full dose of propofol alone. Therefore, the present study was designed to test the hypothesis that ketofol would be a good alternative anaesthetic agent and better than propofol in ECT procedures.
MATERIALS AND METHODS
Our prospective, randomised, double-blind, crossover study included 25 patients with American Society of Anesthesiologists physical status I to II who were referred to our clinic for ECT. The age range was 18 to 65 years. Prior to the study, approval of the Inonu University Local Ethics Committee (acceptance number 2010/162) and written informed consent of each patient and/or their relatives was obtained. Six consecutive ECT sessions were included in the assessment. Patients with pregnancy, cerebrovascular disease, epilepsy, myocardial infarction within the past six months, as well as those using anticonvulsant drugs, were excluded. One of the patients was excluded during the study due to severe hypertension during ECT after four sessions.
The patients were taken into the operating room without any premedication and they were subjected to routine monitoring. Thereafter, patients were randomly assigned into two groups by computergenerated random numbers to receive either ketofol or propofol for the initial ECT. In the following ECT sessions the groups were crossed over to the other agent, respectively (3:3). Ketofol was prepared as a 1:1 mixture of ketamine 10 mg/ml and propofol 10 mg/ml whereas propofol was prepared as propofol 1% solution. Study drugs were drawn up in 20 ml syringes. Determination of the study groups and preparation of the drugs were carried out by an anaesthetist not present in the operating room during ECT sessions. Anaesthesia induction was achieved with 1 mg/kg ketofol (0.5 mg/kg propofol plus 0.5 mg/kg ketamine) or by 1 mg/kg propofol 1% and both were delivered within 30 to 60 seconds.
Consciousness was evaluated by the absence of response to verbal commands and loss of eyelash reflex. If needed, additional doses were administered from the drug remaining in the same syringe and recorded.
After loss of consciousness an isolated forearm technique was performed by inflating the tourniquet that had been applied on the right arm and an electrode was placed on the right hand for electromyography recording. Thereafter, a succinylcholine 0.5 mg/kg bolus was administered intravenously from the contralateral arm. The patients were ventilated with 100% O 2 at 20 breaths per minute. Then a psychiatrist blinded to the study groups administered electrical stimuli through bifrontotemporal electrodes (Thymatron System IV, Somatics Inc., Lake Bluff, IL, USA). In the first session, the patients received ECT with 30 to 50% of the maximum output stimulus depending on the psychiatrist's choice. After the first session, the same psychiatrist organised the stimulus amplitudes according to each patient's clinical outcomes.
Motor seizure duration, electroencephalogram (EEG) seizure duration, and postictal suppression index (PSI) were recorded from the EEG and electromyography traces obtained during the seizure. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MAP), heart rate (HR) and peripheral oxygen saturation values were recorded before the seizure (Tbaseline), after the seizure (T0), and following the ECT session at one (T1), three (T3), five (T5), and 10 (T10) minutes.
The time from the end of succinylcholine administration to recovery of spontaneous breathing, eye-opening and time to obey to verbal commands were recorded separately. Presence of complications such as arrhythmia, laryngospasm and agitation were recorded. The patients were checked for nausea/vomiting and the presence of untoward psychological reactions in the recovery room and on the following day.
A difference of at least six seconds of seizure duration between two groups was considered clinically significant as observed in a previous study 13 . For a power of 0.8 and α=0.05, a sample size of 11 patients in each group was required. Statistical analysis was performed using SPSS for Windows version 13.0 program. All data were reported as mean±SD. Normality for continued variables in groups was confirmed by a Shapiro Wilk test. Unpaired t-test and paired t-test were used. P <0.05 was considered statistically significant.
RESULTS
The mean age for the 13 women and 11 men included in the study was 26 years (range 19 to 46 years) and their mean weight was 70 kg (range 50 to 93 kg). Patients received a total of 144 ECTs in six sessions within a three-days-per-week program. The clinical diagnoses of the patients were schizophrenia in 12, bipolar affective disorder in eight, major depression in two, postpartum psychosis in one and conversion disorder in one patient.
There was no statistically significant difference between ketofol (29±17 seconds) and propofol (28±13 seconds) with regard to motor seizure duration. Although EEG seizure duration was longer with ketofol than propofol (ketofol 41±17 seconds, propofol 38±16 seconds), the difference Tbaseline T0  T1  T3  T5  T10  Time Propofol Ketofol fiGurE 1: Heart rate values using the ketamine:propofol combination (ketofol) and propofol. Tbaseline=before the seizure; T0=after the seizure; T1, T3, T5 and T10=following the ECT session at 1, 3, 5 and 10 minutes repectively. * P <0.05 between groups. fiGurE 2: Systolic blood pressure values using the ketamine:propofol combination (ketofol) and propofol. Tbaseline=before the seizure; T0=after the seizure; T1, T3, T5 and T10=following the ECT session at 1, 3, 5 and 10 minutes respectively. * P <0.05 between groups. was not statistically significant or clinically relevant. EEG seizure duration was below 25 seconds in eight sessions with ketofol and 14 sessions with propofol. The PSI value was higher with ketofol (89.63±7.88) than with propofol (79.74±14.6). Motor seizure duration, EEG seizure duration and PSI value are shown in Table 1 .
The HR at T0 was higher than the baseline value with ketofol, but significantly lower than the baseline value at T1 (P=0.001, P=0.034 respectively). With propofol, HR was significantly higher at T0 and T5 compared with the baseline (P=0.001, P=0.034 respectively). There was a significant difference between the ketofol and propofol in terms of HR at T0 and ketofol led to higher HRs (P=0.03). The SBP, DBP and MAP values were significantly higher at all timepoints in the ketofol group compared with the baseline values (P=0.001). In the propofol group, while SBP was observed to be significantly higher at all timepoints (P <0.004), DBP and MAP values were determined to be higher at T0, T1, T3, and T5 compared with the baseline (DBP P <0.029; MAP P <0.001). The comparison of the two groups revealed differences in SBP at T0 and T1 (P=0.018, P=0.034); in DBP at T0, T1, T3, and T5 (P=0.001, P=0.002, P=0.011, P=0.007); and in MAP at T0 and T5 (P=0.001, P=0.033). Ketofol was found to cause significantly higher increases at all those timepoints compared with the propofol. HR and SBP data are shown in Figures 1 and 2 .
No differences were observed between ketofol and propofol regarding recovery of spontaneous breathing (163±73 and 171±77 seconds, respectively) and eye-opening (321±81 and 304±95 seconds, respectively). Time to obeying commands was significantly longer in the ketofol group (ketofol 484±120 seconds; propofol 424±100 seconds; P=0.006) ( Table 1) .
While an additional dose was required after 53 ECT procedures in the ketofol group and only 32 ECT procedures in the propofol group, the difference was not statistically significant (Table 1) . During recovery, laryngospasm was observed in one case in each group. Moreover, we encountered agitation in one patient during one session, nausea/ vomiting in one patient in one session and atrial arrhythmia in one patient in one session with ketofol. We did not encounter untoward psychological reactions with ketofol.
DISCUSSION
To our knowledge, this is the first reported use of a ketamine:propofol combination (ketofol) for ECT anaesthesia. We compared this to the use of propofol which we previously used routinely in our clinical practice. According to our observations the seizure quality was better with ketofol in comparison to the propofol group. However, we found no statistically significant difference between the ketofol and the propofol groups with regard to motor seizure duration and EEG seizure duration.
Seizure duration has been shown to be prolonged by decreasing the propofol dose and by adding short-acting opioids as adjuvants 14, 15 . In our study, we followed the same principle; the propofol dose was reduced by combination with low-dose ketamine. However, at the doses we used, no significant prolongation was found in the seizure durations.
Previous reports suggest that ketamine provides longer seizure durations than other anaesthetics 1, 3, 16 . Krystal et al 3 retrospectively investigated cases in which ECTs with methohexitone produced seizures lasting shorter than 25 seconds, despite maximal stimulation, and reported that the addition of ketamine at a mean dose of 1.31 (0.7 to 2.8) mg/kg increased seizure duration in 30 of 36 cases. On the other hand, there are also studies suggesting that ketamine does not prolong seizure duration during ECT procedures 17, 18 . Rasmussen et al 17 used ketamine during ECT in 10 patients with no extension of motor and EEG seizure length. They used ketamine at higher doses (1.04 to 3.12 mg/kg) and later in the course they noted that these factors were possible explanations for why ketamine seizures were not longer. In our study, despite the use of lower dose ketamine and propofol, no extension of seizure duration was observed.
However, some investigators have reported that multiple-lead EEGs recorded during ketamine seizures revealed greater ictal power, suggesting that there might be qualitative differences in the seizure between ketamine and methohexitone 17 .
It has been suggested that seizure duration and seizure quality have no relationship [19] [20] [21] . Moreover, studies underline the importance of seizure quality in terms of the clinical efficacy of ECT 3, 20, 21 . It has been suggested that clinical efficacy is primarily correlated with more intense seizure activity with higher amplitudes on EEG and more pronounced PSI 20 . The PSI reflects how quickly the EEG amplitude decrease 'flattens' just after the end of seizure and is more directly related to the intensity or generalisation of seizure than to its duration 19 . Under that circumstance we believe that ketofol can be more suitable for enhancing seizure quality and clinical effectiveness of ECT. However, the clinical efficacy and therapeutic response of study drugs could not be evaluated in this study because of the crossover design.
In relation to haemodynamic parameters, propofol appeared to provide better management of the cardiovascular response to ECT. Studies comparing ketofol and propofol have shown that ketofol provides better haemodynamic stability 9, 10 . In some studies, drugs were delivered during regional anaesthesia for achievement of adequate deep sedation. Therefore, ketofol may be more advantageous than propofol in preventing hypotension or maintaining stable haemodynamics after anaesthesia induction. In our study, we did not evaluate the haemodynamic parameters after anaesthesia induction. However, ketofol was observed to be less effective than propofol in managing the cardiovascular sympathetic response during seizure activity. Krystal et al 3 were able to perform haemodynamic evaluations in only 12 of 36 cases in which ketamine was used. They found no difference between ketamine and methohexitone in relation to peak HR and SBP, whereas DBP was found to be higher among patients receiving ketamine. Rasmussen et al 13 found that blood pressurewas higher in the ketamine group than in the methohexitone group. Ketofol may provide a better haemodynamic stability compared with the ketamine alone. However, we cannot comment on this because our study did not include a ketamine group.
While there was no difference between the groups in terms of early recovery criteria including time to spontaneous breathing and eye-opening, time to obeying verbal commands was more prolonged in the ketofol group. In a study by Andolfatto et al 10 , recovery time was 14 minutes in the emergency cases that had received ketofol in the 0.2 to 2.7 mg/kg range. In their study there was no propofol group and unlike our study, recovery criteria were assessed by a modified Aldrete Scale. Singh et al 22 used regional anaesthesia on paediatric patients and infused a mixture of propofol and ketamine for sedation. They utilised a modified Aldrete Scale as the recovery criteria and found no difference. The conflicting results between our study and the abovementioned studies may be due to the different age group and different procedures.
Krystal et al 3 found side-effects in three of 36 cases with ketamine. Two patients exhibited agitation during recovery from anaesthesia and one developed hallucinations lasting until the next day. This case was an alcoholic patient who had received highdose ketamine (2.8 mg/kg). Ketamine is known to cause untoward psychological reactions such as hallucinations in a dose-dependent way. Therefore some authors believe that this side-effect can be prevented by using an adjuvant at a subanaesthetic dose 7 . Nagato et al found that propofol could inhibit psychomimetic activity associated with ketamine by inducing γ-aminobutyric acid type A receptor activation in animal studies 23, 24 . Although some of our patients were suffering from schizophrenia, an untoward reaction was not encountered during ketofol administration in any of the sessions. Only one patient, who had a bipolar affective disorder, exhibited agitation for a brief period after the procedure. Thus ketofol use may be a safer strategy for prevention of untoward psychological reactions.
In the current study, we prepared ketofol mixture at 1:1 ratio as in previous studies 10, 11, 25 . The initial dose was 1 mg/kg in both groups, but the requirement for additional doses was more frequent in the ketofol group. Daabiss et al compared two different mixtures of propofol and ketamine and found that while the sedation scores were the same, side-effects were reduced and recovery was shortened with a lower dose of ketamine 26 . Therefore, we believe that varying ketamine and propofol rates can be tested in order to improve requirement for additional dose, haemodynamics, recovery and side-effects.
We evaluated patients' various clinical diagnoses in our study. Ketofol may have different effects on distinct clinical diagnoses like schizophrenia or major depression. In some studies investigators have observed rapid and strong antidepressant effects at subanaesthetic doses of ketamine in medical and ECT treatment-resistant depression patients 27, 28 . Zarate et al used a single dose of intravenous ketamine (0.5 mg/kg in 40 minutes) and observed improvement in depression starting between 110 minutes and seven days 27 . Okamoto et al compared ketamine and propofol in ECT anaesthesia for treatment-resistant depression patients. They observed an earlier recovery in patients who received ketamine 5 . Therefore it is possible that a subanaesthetic dose of ketamine, such as that used in our study, may cause more rapid recovery in major depression patients. However, future studies are required on this issue.
In summary, ketofol used at a 1 mg/kg dose for ECT procedures yielded similar seizure durations as propofol, but produced a better seizure quality. Accordingly, we conclude that ketofol can be an alternative agent to enhance the seizure quality and possibly clinical efficiency of ECT. However, future studies are required to evaluate the effects of
